In a wonderful article written by Gauri kamath in IIT Madras journal shastra, in march-april 2023 edition oncoseek Bio was featured.

Dr Suresh Poosala and Dr Bharadwaja Vadloori have participated in the India EMBO lecture course on ' Microphysioligical Systems :Advances and Applications in human relevant research' from 31st October to 4th November 2022 at Centre for Cellular and Molecular Biology Hyderabad.

Dr Suresh Poosala delivered a lecture and gave a bird's eye view of the various research programs that we do at Oncoseek Bio.

Dr Bharadwaja Vadloori presented a poster on the NASH spheroid model that we are developing at Oncoseek Bio.

Dr Suresh Poosala participated in the panel discussion on the entrepreneurship journey with MPS models and shared his experience and guided and mentored the young budding entrepreneurs.

Oncoseek Bio has signed an MoU with National Institute of Animal Biotechnology (NIAB), Hyderabad to perform collaborative cutting edge translational research.

Oncoseek Bio receives investments and support from USISTEF, DBT and friends & family.

Oncoseek Bio is in association with three hospitals to make translational research useful for the patients.

UoH’s BioNEST has been selected as the best emerging bio-incubator, Oncoseek Bio is incubated here.

Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the U.S.–India Science & Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”

This project was one of the 11 selected out of 520 proposals that were received and evaluated. This is the second competitive grant that the company is receiving. Earlier it has received a grant from BIRAC, Govt. of India to develop a platform to screen the potential drug candidates for Covid-19.

UoH incubated startup Oncoseek Bio bags grant for Covid-19 research

Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the U.S.–India Science & Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”

This project was one of the 11 selected out of 520 proposals that were received and evaluated. This is the second competitive grant that the company is receiving. Earlier it has received a grant from BIRAC, Govt. of India to develop a platform to screen the potential drug candidates for Covid-19.

USISTEF Covid-19 challenge grant for UoH start-up Oncoseek Bio

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has resulted in a global health and economic crisis of unprecedented scale. The high transmissibility of SARS- CoV-2, combined with a lack of population immunity and prevalence of severe clinical outcomes, urges the rapid development of effective therapeutic counter measures. To combat this pandemic and in keeping with its mission and vision, the U.S.–India Science & Technology Endowment Fund (USISTEF) announced a call for proposals under the category of COVID-19 Ignition Grants in April 2020. After a rigorous binational review process, USISTEF announced awards to 11 bilateral teams, proposing out-of-the-box, innovative ideas that address the COVID-19 challenge.

UoH Startup bags grant from US-India R&D fund

A start-up company incubated at the University of Hyderabad (UoH) has won a US-India Science and Technology Endowment Fund (USISTEF) ignition grant for its "Novel therapeutic strategy to fight against Covid-19". The proposal by Novel Oncoseek Bio Pvt Ltd., was one of the eleven that were selected from 520 proposals that were received and evaluated. The company is one of the start-up companies of ASPIRE-BioNEST at UoH had earlier received a grant from BIRAC, Government of India to develop a platform to screen the potential drug candidates for Covid-19.

UoH start-up gets US-India science grant for Covid

Oncoseek Bio Pvt Ltd, one of the start-up companies of ASPIRE-BioNEST at University of Hyderabad (UoH) has received the US–India Science and Technology Endowment Fund (USISTEF) under Covid-19 Ignition Grants for a “Novel therapeutic strategy to fight against Covid-19”.

UoH start-up bags Covid-19 challenge grant from USISTEF

Start-up company incubated at the University of Hyderabad (UoH) has won a US-India Science and Technology Endowment Fund (USISTEF) ignition grant for its "Novel therapeutic strategy to fight against Covid-19".The proposal by Novel Oncoseek Bio Pvt Ltd., was one of the eleven that were selected from 520 proposals that were received and evaluated.

University of Hyderabad start-up Oncoseek Bio bags US-India Covid project

Oncoseek Bio Pvt Ltd, a start-up incubated at the University of Hyderabad has received the United States-India Science and Technology Endowment Fund (USISTEF) for its strategy developed to fight Covid-19.

Star-tup at Hyderabad University receives USISTEF fund to develop therapeutically COVID-19

A start-up incubated at the University of Hyderabad has received the United States India Science and Technology Fund (USISTEF) under the COVID-19 inflammatory awards for a new therapeutic strategy to fight the virus. Oncoseek Bio Pvt. Ltd., one of the start-ups of UoH’s ASPIRE-BioNEST incubators, was one of 11 out of 520 proposals selected for the fund.

This is the second competitive award the company has received. Earlier, it received an award from BIRAC, Govt. of India, to develop a platform to investigate the potential drug candidates for Covid 19. Oncoseekbio Pvt Ltd, which has been with ASPIRE-BioNEST since 2019, has a vision to develop in vitro and in vivo platforms for specific therapeutic screening diseases.

BIRAC To Invest In OncoSeek Bio For Facilitating Covid-19 Cure

Hyderabad-based biotech startup OncoSeek Bio has been selected for funding from the state-run Biotechnology Industry Research Assistance Council (BIRAC) for developing a potential cure for the Covid-19 virus.

Incubated at the University of Hyderabad (UoH), OncoSeek Bio will develop an in vitro lung organoids. These organoids are simply a 3D tissue-engineered mini lung which has the capacity to replicate the aspects of lung tissues. Organoids can help researchers to find drugs for better treatment of Covid-19.

Hyderabad startup bags BIRAC funding for Covid-19 project

In a boost to efforts aimed at tackling the pandemic, a start-up incubated at the University of Hyderabad (UoH) has been selected for Covid-19 funding by the Biotechnology Industry Research Assistance Council (BIRAC).

OncoSeek Bio Pvt Ltd will receive funding support for developing an in vitro Lung Organoid model, from BIRAC which comes under the Union Science and Technology Ministry's Department of Biotechnology (DBT).

UoH-incubated firm gets DBT funding

A startup incubated at the University of Hyderabad (UoH) has been selected for financial support for developing an ‘in vitro lung organoid model’.

“Current animal models available for research on COVID-19 are either difficult to get into India or create them in time, to address the pandemic. The company envisages creating novel in vitro platforms for the research under the support,” said founder-CEO of OncoSeek Bio Pvt. Ltd., Suresh Poosala, on Sunday.

UoH incubated startup to receive Birac funding

OncoSeek Bio Pvt Ltd, an incubated startup of University of Hyderabad (UoH), has been selected for Covid-19 funding by Biotechnology Industry Research Assistance Council (Birac).

According to a press release issued by UoH, the startup has been selected for financial support to develop an in vitro lung organoid model. OncoSeek Bio is one of the 16 projects of the 500 proposals received by the Birac under the department of biotechnology (DBT) for funding support for the Covid-19 research consortium.

OncoseekBio has successfully organized the first International Conference Series on 3R's Research & Progress

Transtoxbio portfolio finds client in OncoSeek Bio Pvt. Ltd.’s preclinical Discovery and Services

TranscellOncologics’s cell based platforms portfolio,Transtoxbio, inks an agreement with OncoSeek Bio Pvt. Ltd (OSB), a Hyderabad based boutique Contract Research Organization.

Oncoseek Bio & Transtoxbio Collaboration

As part of this engagement OSB sources various cells and cellular platforms from Transtoxbio portfolio to enable its in-house exploratory R&D, discovery and screening on novel platforms that use various monolayers or 3D structures including spheroids/organoids/microfluidics and other printed technologies. OSB also plans to use Transtoxbio’s new league of human sourced primary mature cells and primary stem cells (CD34+ cells - TRANS-HSC) in generating new relevant animal models for several disease conditions that have no true preclinical animal model representation currently for pharmaceutical research. OSB is keen to treat Transtoxbio portfolio as itsmain cell based platforms or free suspended cells supplier for all its preclinical models and services to be offered to global industry and for its own discovery programs.